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Abstract: Waddington’s epigenetic landscape, a famous metaphor in developmental biology, depicts
how a stem cell progresses from an undifferentiated phenotype to a differentiated one. The concept
of “landscape” in the context of dynamical systems theory represents a high-dimensional space,
in which each cell phenotype is considered as an “attractor” that is determined by interactions
between multiple molecular players, and is buffered against environmental fluctuations. In addition,
biological noise is thought to play an important role during these cell-fate decisions and in fact controls
transitions between different phenotypes. Here, we discuss the phenotypic transitions in cancer from
a dynamical systems perspective and invoke the concept of “cancer attractors”—hidden stable states
of the underlying regulatory network that are not occupied by normal cells. Phenotypic transitions
in cancer occur at varying levels depending on the context. Using epithelial-to-mesenchymal
transition (EMT), cancer stem-like properties, metabolic reprogramming and the emergence of therapy
resistance as examples, we illustrate how phenotypic plasticity in cancer cells enables them to acquire
hybrid phenotypes (such as hybrid epithelial/mesenchymal and hybrid metabolic phenotypes)
that tend to be more aggressive and notoriously resilient to therapies such as chemotherapy and
androgen-deprivation therapy. Furthermore, we highlight multiple factors that may give rise to
phenotypic plasticity in cancer cells, such as (a) multi-stability or oscillatory behaviors governed
by underlying regulatory networks involved in cell-fate decisions in cancer cells, and (b) network
rewiring due to conformational dynamics of intrinsically disordered proteins (IDPs) that are highly
enriched in cancer cells. We conclude by discussing why a therapeutic approach that promotes
“recanalization”, i.e., the exit from “cancer attractors” and re-entry into “normal attractors”, is more
likely to succeed rather than a conventional approach that targets individual molecules/pathways.
Keywords: cell fate decision; cancer attractors; gene network dynamics; EMT; therapy resistance;
intrinsically disordered proteins
1. Introduction
“The woods are lovely, dark and deep, but I have promises to keep, and miles to go before I sleep,
and miles to go before I sleep.”
—Robert Frost
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Waddington’s epigenetic landscape [1] depicting how a stem cell progresses from an undifferentiated
phenotype to a differentiated one is one of the most famous and powerful metaphors in developmental
biology. Conceptually, the differentiation of a stem cell is represented by a ball rolling downhill
through a rugged landscape of bifurcating valleys, each representing a possible cell fate (Figure 1A).
The valleys continue bifurcating and the ball finally enters one of many sub-valleys at the foot of
the hill. These sub-valleys represent terminally differentiated states, i.e., cell fates. The cell is held
permanently, unless perturbed significantly, in the terminally differentiated state by high ridges, i.e.,
valley walls. The deeper the valley, the more canalized the cell fate. The epigenetic landscape in the
context of dynamical systems theory represents a high-dimensional state space in which each cell fate
is an “attractor” shaped by the architecture of its regulatory interaction network [2]. It is generally held
that cell fate is essentially irreversible; it follows the “arrow of time”. However, recent developments
in cellular reprogramming have illustrated that a terminally differentiated cell can be forced to switch
states (phenotypes) and acquire an undifferentiated state by supraphysiological overexpression of
a cocktail of transcription factors (TFs) [3]. Similarly, cancer has been also shown to be ‘reversed’
to a non-malignant phenotype, thereby raising questions about the sufficient and necessary role of
mutations in cancer progression [4].
In a dynamical system, an “attractor” (steady state) represents a set of values of the variables
towards which the system evolves from a wide variety of starting conditions, and is robust to
slight perturbations. Cell phenotypes are regulated by underlying gene regulatory networks (GRNs)
(Figure 1B). GRNs are dynamical systems that start from context-dependent conditions, develop
temporally due to the mutual interactions between molecular regulators (genes, proteins, microRNAs
etc.) and later settle down into “attractors” (stable cell phenotype), each of which is characterized
by a unique gene expression pattern (Figure 1C). Different possible steady states (“attractors”) of a
given GRN can be identified by mathematically modeling its dynamics; each attractor is associated
with a steady-state probability of finding the system in that particular configuration. Together, this set
of attractors—with their relative probabilities of being realized by the system—define a “landscape”.
Representing a stable cell phenotype as an “attractor” has helped realize the basic concepts of both
single-cell stochasticity and population determinism, i.e., single cells can shift from one attractor to
another due to noise, without altering the overall population structure. This perspective facilitates
viewing biological systems from the perspective of statistical mechanics, where a macrostate (a cell
population structure) can correspond to multiple microstates (phenotypic heterogeneity at a single-cell
level) [5].
The concept of an “attractor” representing a cell phenotype (cell fate) has been widely used
to understand lineage specifications during development. Usually, lineage commitment between
sister cell-fates (i.e., sharing a common progenitor) is a binary branching process that is governed
by a decision-making circuit consisting of two transcription factors X and Y that mutually inhibit
each other and can also self-activate [2], referred to as a “self-activating toggle switch” [6]. X and
Y are usually the master regulators of the two sister cell-fates. Such a “self-activating toggle
switch” usually generates three stable “attractors’ that are characterized by Xhigh/Ylow, Xlow/Yhigh and
Xmedium/Ymedium corresponding to two differentiated cell fates and an undifferentiated progenitor state
respectively [2,6,7] (Figure 1A). Such “self-activating toggle switches” governing lineage commitments
have been studied in various scenarios, such as the Gata1/PU.1 switch in the lineage commitment of
multipotent progenitor cells [8], the Cdx2/Oct4 switch in the differentiation of a totipotent embryo [9],
the Gata6/Nanog switch in the branching process of inner cell mass [10] and the T-bet/Gata3 switch
in the lineage specification of the T-helper cells [11].
The concept of an “attractor” representing a cell phenotype is used not only in understanding
embryonic development, but also in elucidating cancer initiation and progression. Cancer cells are
regarded as abnormal cell phenotypes, i.e., “cancer attractors”, and are believed to be the “hidden
stable states” enabled by the regulatory networks that are not commonly occupied by normal cells [10].
Accesses to “cancer attractors” can be facilitated by genetic events (mutations) and/or non-genetic
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events (contextual signals and biological noise). For example, loss-of-function mutations in tumor
suppressor genes such as TP53 and BRCA and/or gain-of-function mutations in proto-oncogenes
such as MYC and RAS facilitate oncogenic properties of cells [12]. In addition to genetic events,
the microenvironment surrounding cells can also promote tumorigenesis. For instance, overexpression
of a stromal proteinase-matrix metalloproteinase-3 (MMP3) in both mouse phenotypically normal
mammary epithelial cells (Scp2) and the mammary glands of transgenic mice, results in a reactive
stroma and eventually leads to infiltrative mammary tumors [13]. Similarly, overexpression of the
platelet-derived growth factor subunit B (PDGF-B) in the non-tumorigenic immortalized human
keratinocytes (HaCaT) leads to a conversion to epithelial tumor cells through stromal cell activation [14].
These examples suggest that the probability to get access to “cancer attractors” can be enhanced due
to gene mutations and/or contextual signals in the microenvironment. Furthermore, transitions can
happen among “cancer attractors” to benefit cancer cells for survival and progression, referred to as
phenotypic plasticity in cancer [15].
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Figure 1. Schematic illustration of Waddington’s epigenetic landscape. (A) W ddingto ’s epigenetic
landscape (a opted and revised from [1]). The balls with different colors on the landscape represent
different cell phenotypes, each settles steadily in one of the sub-valleys at the foot of the hill. X and Y are
the master regulators driving a cell to attain the phenotypes “1” and “2” respectively. The phenotype
“0”, characterized by the co-expression of bot X and Y at a medium level Xmed/Ymed, represents the
progenitor state of the two differentiated states “1” and “2” which are characterized by Xhigh/Ylow
and Xlow/Yhigh respectively. Due to inherent stochasticity in the progenitor cell “0”, the level of X (Y)
becomes higher tha that of Y (X). This asymmetry can trigger a cascad of events where the levels
of X (Y) continually increase and those of Y (X) continually decrease, because X (Y) can progressively
repress its repressor Y (X) strongly, rendering its own inhibition by Y (X) ineffective. Consequently,
the cell attains the differentiated state Xhigh/Ylow (Xlow/Yhigh). (B) Sch matic illust ation of a gene
regulatory network (GRN) governing the differentiation of “1” to two lineages “1_1” and “1_2”.
The nodes A–F represent different genes whose regulatory behaviors usually can be approximated by
the interplay between two mast r regulators X and Y as afor mentioned. Various kinds of regulation
can be found in the GRN, such as transcriptional activation, represented by red arrows, transcriptional
inhibition, represented by blue bar-headed arrows, and self-activation, represented by circled arrows.
(C) Schematic illustration of a heatmap that depicts the gene expression patterns of different cell
phenotypes. The two sister lineages “1_1” and “1_2” are characterized by different gene expression
patterns, i.e., relatively high expression of one gene set and low of another. The progenitor of “1_1”
and “1_2”, i.e., “1”, usually co-expresses both sets of genes at some intermediate level.
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In this review, we invoke the concept of “cancer attractors” and discuss the phenotypic plasticity
of cancer cells from a dynamical systems perspective. Using epithelial-to-mesenchymal transition
(EMT) and the acquisition of stem-like properties, metabolic reprogramming and the emergence
of drug/hormone resistance in cancer as examples, we illustrate how non-genetic heterogeneity
regulates phenotypic plasticity of cancer cells that enables them to acquire phenotypes that are
notoriously aggressive and resilient to drug/hormone treatment. With enhanced plasticity, cancer
cells can potentially rewire the regulatory network to access latent “attractors” suggesting that cancer
initiation and progression may, at least in part, be due to a “de-canalization” of normal cell fates.
Finally, we highlight the potential role of intrinsically disordered proteins (IDPs) that comprise a vast
majority of the proteins over-expressed in cancer, and how biological noise due to IDP conformational
dynamics may further enhance phenotypic plasticity of cancer cells. Since the perspective is intended
to encourage cross pollination of ideas between biologists, especially cancer biologists, and physicists
interested in exploring the physics of biology, technical jargon is limited to its minimum and equations
are omitted.
2. Cancer Cell States: The Hidden “Attractors”
Cell phenotypes manifested during embryonic development are governed by specific gene
regulatory networks (GRNs) (Figure 1B). The GRNs give rise to an epigenetic landscape consisting of
multiple stable gene expression patterns (Figure 1C) characterizing various “attractors”, i.e., “stable
states” or “phenotypes” [16,17]. The “attractors” are usually self-stabilized and robust to local
perturbations [18]. However, certain transitions between “attractors”, i.e., phenotypic switching,
can be triggered by regulatory signals, such as cytokines and noise due to gene expression as well as
IDP conformational dynamics in addition to mutational events [19,20].
Cancer cells are viewed as abnormal cell types that are characterized by hallmarks such as
sustained proliferation, invasion and metabolic reprogramming [21]. Extensive inherent heterogeneity
of cancer cells has been shown at both the genetic level due to genomic instability [22], and
the non-genetic level, resulting from cellular plasticity, i.e., the ability of cells to switch between
phenotypes [23,24]. The examples of non-genetic heterogeneity in cancer include, but are not
restricted to, epithelial-to-mesenchymal transition (EMT) [25], acquiring “stem-like” properties [26],
and metabolic plasticity [27,28]. In certain cases, these processes have been shown to be coupled.
For instance, cells undergoing EMT can acquire stem-like properties [29], stem-like properties associate
with metabolic changes [30], and metabolic programming involves changes in EMT [27,31,32].
This extensive plasticity of cancer cells may enable the occupancy of the “attractors” that are
unpopulated or inaccessible during embryonic development, or equivalently, acquire phenotypes not
usually observed during development or homeostasis. The concept of “cancer attractors” representing
abnormal cell types was first proposed by Stuart Kauffman in 1971 [33] and recently revisited by
Huang, Ao and colleagues [34,35]. In the following sections, we will review progress in elucidating
the phenotypic plasticity of cancer cells from the dynamical systems perspective, namely, by viewing
cancer cell phenotypes as different “cancer attractors” in the state space determined by the underlying
regulatory networks.
3. Cell Fate Decision-Making during Epithelial-to-Mesenchymal Transition
Epithelial-to-Mesenchymal Transition (EMT) is a trans-differentiation program by which epithelial
cells lose their cell-cell adhesion and gain migratory property to become mesenchymal cells.
Both EMT and its reverse—Mesenchymal-to-Epithelial Transition (MET)—play crucial roles during
embryogenesis (during processes such as gastrulation, neural crest delamination and myogenesis) and
tissue repair (during wound healing and fibrosis) [36]. However, EMT may sometimes be “hijacked”
by carcinoma cells to acquire enhanced migratory properties that can contribute to metastasis and/or
acquired therapy resistance [37,38]. Moreover, the EMT transcription factors (EMT-TFs), such as ZEB
(zinc finger E-box-binding homeobox) and SNAIL (zinc finger protein SNAI1), have even been shown
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to play an important role in tumor progression in non-carcinomas, such as melanoma [39,40] and
glioblastoma [41,42].
During metastasis, cancer cells do not always undergo a complete EMT, instead a partial
EMT (leading to a hybrid epithelial/mesenchymal (E/M)) phenotype, in which cells exhibit both
epithelial (cell-cell adhesion) and mesenchymal (migration and/or invasion) traits, has often been
observed [43–45] (Figure 2A). Cells in a hybrid E/M phenotype can migrate collectively as a cluster
instead of migrating individually like a cell that has undergone a complete EMT. These clusters of
circulating tumor cells (CTCs) associate with up to 50-fold higher metastasis potential and higher
tumor-initiating potential compared with single CTCs [43,46], thus being proposed as the primary
“bad actors” of metastasis [44].
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Figure 2. Schematic illustration of the quasi-potential landscape for epithelial-to-mesenchymal
transition (EMT) in 3-dimensional space (A) and 2-dimensional projection (B). In (A), the basins
of attra tion depicting the attractors “E”, “E/M” nd “M” are labeled respectively along with the
cartoons representing the epithelial (tight cell-cell adhesion, cobblestone shaped), hybrid E/M (some
cell-cell adhesion and invasive) and mesenchymal (no cell-cell adhesion, invasive and spindle-shaped)
phenotypes. The quasi-potential of “attractors”, i.e., stability of “attractors”, is derived from the
probability of finding cells in that “attractors”. Lower potential here represents more stable “attractor”
in the landscape. The “potential well” depicted here is an analog of “valleys” in Waddington
epigenetic la scape.
To understand the epithelial-mesenchymal plasticity, i.e., transitions among epithelial (E),
hybrid E/M and mesenchymal (M) phenotypes, a core EMT regulatory circuit consisting of two
transcription factor families—ZEB and SNAIL and two microRNA famili s—miR-200 and miR-34,
has been ch racterized. Hig expression of th transcrip ion factors ZEB and SNAIL promotes a
mesenchymal phenotype while high expression of microRNAs miR-200 and miR-34 maintains an
epithelial phenotype. Two mathematical models [47–49] that were independently proposed have been
applied to analyze the dynamics of the core EMT circuit. Both models elucidate that (1) the core EMT
decision-making circuit functions as a “three-way” switch, that can give rise to three stable states—“E”
characteriz d by (E markerhigh/M markerlow), “M” characteriz d by (E markerlow/M markerhigh) and
“E/M” characterized by (E markermedium/M markermedium). (2) EMT is a two-step processes—from
“E” to “E/M” to “M” [47,48]. Once the cells transition into a mesenchymal phenotype, the stable
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state or phenotype “M” can be self-stabilized, by feedback loops such as increased inhibition of
ZEB on miR-34 [50], and/or the decreased inhibition of miR-200 on the endogenous TGF-β [48,50].
The landscape approach has been utilized to quantify the transition processes among these three stable
states, i.e., “attractors”—“E”, “E/M” and “M” [51]. This study suggested that attainment of a hybrid
E/M state often decreases the required strength of EMT-inducing signals to initiate EMT, i.e., pulling
cells out of the stable state “E”, thus enabling cancer cells to be more plastic [51].
The hybrid E/M phenotype has been observed in circulating tumor cells (CTCs), primary tumors,
metastases, and 3D reconstructions of 2D histological sections [44,52], but it has tacitly been largely
assumed as a “metastable” or transient phenotype [53]. However, recently, in part driven by these
mathematical models, a stable hybrid E/M phenotype has been observed in the non-small cell lung
cancer (NSCLC) cell line−H1975, in which individual cells co-express an epithelial marker—E-cadherin
and a mesenchymal marker−Vimentin [54]. These cells can maintain their hybrid E/M phenotype
for over two months after multiple passages, thus being characterized as a stable phenotype [54].
Moreover, such an integrated computational-experimental analysis has also helped identify two
transcription factors GRHL2 (grainyhead like transcription factor 2) and OVOL2 (ovo-like zinc finger 2)
that can stabilize the hybrid E/M phenotype [54–56]. Knockdown of either GRHL2 or OVOL2 in H1975
cells destabilized the hybrid E/M phenotype and cells progressing to a complete EMT state [54]. Thus,
these “phenotypic stability factors” (PSFs) GRHL2 and OVOL [57] act as “critical molecular brakes”
by preventing “cells that have gained partial plasticity from crossing the line to undergo complete
EMT” [58]. Of note, there may exist multiple hybrid E/M phenotypes characterized by different
gene expression profiles [56,59], and other players such as JAG1 (ligand of cell-cell communication
pathway—Notch signaling) and ∆NP63α can also act as PSFs [60,61]. EMT and MET need not be
symmetric [47], i.e., EMT and MET could potentially proceed via different hybrid E/M phenotypes,
that enables cancer cells to have more phenotypic plasticity (Figure 2).
4. EMT and Stemness
Cancer cells undergoing EMT can acquire stemness, i.e., stem-like properties or tumor-initiation
potential [29], and thus behave operationally as Cancer Stem Cells (CSCs) as observed in multiple
solid tumors [62]. The coupling between EMT and stemness is finely regulated. On the one hand,
EMT promotes the acquirement of stemness in breast [29,63] hepatocellular [64], pancreatic [65] and
colorectal [66] carcinomas; on the other hand, repression of EMT is required for tumor initiation and
metastatic colonization [67–69].
As the first step to understand the coupled decision-making of EMT and stemness, Jolly et al. [70]
formulated a mathematical model to analyze the dynamics of the coupled decision-making circuits of
EMT-ZEB/miR-200 and stemness-LIN28/let-7 [71]. It suggests that the “stemness window” is most
likely to lie at an intermediate position on the “EMT axis” with E and M phenotypes as the two ends.
Further, this positioning of “stemness window” can be adjusted and the phenotypic stability factors
such as OVOL promote the association of a hybrid E/M phenotype with stemness, a prediction that has
been supported by recent experimental work. For instance, HMLER breast cancer cells co-expressing
both epithelial and mesenchymal genes, thus being characterized as hybrid E/M cells, exhibited
highest mammosphere formation potential compared with epithelial and mesenchymal HMLER
cells [72]. Besides, Cancer Stem Cell (CSC)-enriched population resides in a hybrid E/M phenotype of
triple-negative breast cancer cells [73]. Last but not least, a subpopulation of normal mammary cells,
accompanied by both epithelial-like and mesenchymal-like characteristics, i.e., hybrid E/M phenotype,
displays the highest mammosphere-formation capacity [74]. Thus, a biphasic relationship between
stemness and EMT—stemness increases initially during EMT progression, but then subsides as cells
complete EMT—seems to be the emerging notion [43,75,76].
CSCs have also been observed to display enriched drug resistance [77]. For example, a hybrid
E/M phenotype has been reported to be resistant to paclitaxel and salinomycin [78]. Moreover,
adaptive drug resistance involves transitioning to a CD24highCD44high state [79]—a proposed signature
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for hybrid E/M phenotype [72]. Future work on quantifying the landscape [80] for the coupled circuits
of EMT and stemness, along with a better mechanistic understanding of drug resistance pathways,
are required to generate valuable insights into the EMT-stemness interplay.
5. Metabolic Reprogramming and EMT
Abnormal metabolism is an emerging hallmark of cancer [21,81]. Unlike normal cells, cancer
cells mainly utilize glycolysis for ATP production even in presence of oxygen, a phenomenon referred
to as aerobic glycolysis or the Warburg effect [82]. Although aerobic glycolysis has been proposed
to be the dominant metabolism phenotype in cancer cells [83,84], emerging evidence shows that
mitochondria in cancer cells are actively functioning and oxidative phosphorylation (OXPHOS) can
enhance metastasis [85–90].
As the first step to understand the metabolic plasticity in cancer, Yu et al. [91] constructed a core
metabolism regulatory network consisting of AMPK and HIF-1—master regulators for OXPHOS and
glycolysis, respectively—and ROS (reactive oxygen species) that mediates the interplay between AMPK
and HIF-1. This AMPK:HIF-1:ROS regulatory network enables three stable states—(pAMPKhigh/HIF-1low),
(pAMPKlow/HIF-1high) and (pAMPKmedium/HIF-1medium)—corresponding to an OXPHOS, a glycolysis
and a hybrid OXPHOS/glycolysis metabolic phenotype respectively (pAMPK denotes phosphorylated
AMPK, i.e., the active form of AMPK). The hybrid metabolic state, in which cancer cells can utilize
both glycolysis and OXPHOS, facilitates relatively high plasticity for ATP production and proliferation
for cancer cells. The hybrid metabolism phenotype can be stabilized by increased HIF-1 activity, high
oncogene (MYC, RAS, c-SRC) activity and high mitochondria ROS production in cancer cells compared
with that in normal cells [91].
The hybrid metabolism phenotype proposed by the aforementioned modeling work has been
observed in many experimental studies to be associated with metastatic potential. The supermetastatic
human tumor cells SiHa-F3 by in vitro selection and the mouse melanoma cells B16F10, B16-M1 to
M5 by in vivo selection have an increased OXPHOS activity together with an enhanced invasive
activity [92]. The non-small cell lung carcinoma A549 cells undergoing EMT induced by TGF-β show
elevated respiration [27]. The metastatic breast cancer cells 66cl4 and 4T1 have both enhanced oxidative
as well as glycolytic metabolism accompanied by increased extracellular acidification rate and oxygen
consumption rate compared with non-metastatic 67NR cells [93]. In addition, cells in the hybrid
metabolism phenotype can maintain ROS at a moderate level [91], thus avoiding excessive DNA
damage [94] while using ROS signaling to promote metastasis [95]. Moreover, cells in the hybrid
phenotype can simultaneously produce energy and generate biomass for proliferation [30]. Therefore,
a combination therapy that target the hybrid metabolism phenotype, i.e., blocking both glycolysis and
OXPHOS in cancer cells, could be relatively more effective [30,91] than the therapy targeting only one
metabolic pathway.
Of note, regulation of metabolic plasticity has been shown to be coupled with the EMT
decision-making [31]. EMT enhances glycolysis in MCF-7 and BT-474 cells [96] while shifts metabolism
from glycolysis to OXPHOS in MCF10 cells [97]. Fatty acid oxidation is more utilized in the
mesenchymal breast cancer cells D492M than that in epithelial cells D492 (D492M cells are isolated
following a spontaneous EMT in D492 cells) [32]. Blocking fatty acid oxidation in MDA-MB-231
cells decreases their migratory and colony-formation properties, suggesting multiple feedback loops
between regulatory circuit of metabolism, EMT and stemness [90]. This situation remains to be clarified
on the basis of models.
Metabolic plasticity has also been observed in CSCs. Epithelial-like CSCs, characterized by
ALDHhigh, have higher oxygen consumption rate and lower glycolytic activity compared with the
mesenchymal-like breast CSCs, characterized by CD44highCD24low [98,99]. Recent work highlighted
that ALDHhigh cells may exhibit a hybrid E/M state [74]. Future work to analyze the coupled
decision-making of metabolism, EMT and stemness needs to be done to comprehensively chart
the stable states characterized by varied EMT, stem-like property and metabolism traits, while taking
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into consideration the direct coupling between gene expression and metabolites, at least partly through
epigenetic mechanisms [100].
6. EMT and Therapy Resistance
EMT has been associated with both de novo and acquired resistance. De novo resistance implies
intrinsic refractory response of patients, whereas acquired resistance refers to cases where patients first
respond to therapy but later relapse. A relationship between EMT and de novo resistance has been well
studied in cases of targeted therapy. For instance, increased levels of E-cadherin were associated with
sensitivity to EGFR kinase inhibitors such as gefitinib in non-small-cell lung cancer (NSCLC) cell lines,
and pre-treatment of resistant cell lines to induce E-cadherin levels improved their sensitivity [101].
Similarly, knockdown of the levels of SLUG, an EMT-TF, in de novo trastuzumab-resistant HER2+ breast
cancer cells can drive them to being sensitive to trastuzumab [102]. Besides, recent in vivo reports that
questioned an indispensable role of EMT in metastasis only strengthened a potential causal role of
EMT in driving chemoresistance. For example, knocking down TWIST or SNAIL sensitized tumors
to gemcitabine in pancreatic cancer mouse models [103], and miR-200 overexpression abrogated
resistance to cyclophosphamide, a drug commonly used in breast cancer [104]. Taken together, these
studies suggest that cellular plasticity mediated by EMT can act as a switch enabling cells to “enter” and
“exit” a drug-resistant cell state dynamically. Recent mathematical modeling attempts that investigate
the crosstalk among signaling players have highlighted that non-genetic heterogeneity can drive this
dynamic “entry” into and “exit” from a stem-like therapy-resistant state [70,71,80,105,106].
This dynamic “entry” and “exit” may also underlie acquired or adaptive drug resistance, where
different therapies may induce cells to access the “cancer attractors” which are relatively inaccessible
otherwise, but can be used to play “hide-and-seek” with different therapies. For instance, in ovarian
cancer, treatment with chemotherapeutic drugs such as cisplatin, doxorubicin, and paclitaxel can
reversibly increase a small population of CXCR4high cells that is drug-resistant, mesenchymal-like, and
has enhanced tumor-initiation potential [107]. Other examples of adaptive resistance include melanoma
cells switching to a NGFRhigh state upon exposure to RAF/MEK inhibitors [108], NSCLC cells
upregulating ZEB1 on prolonged exposure to increasing concentrations of erlotinib [109], vemurafenib
driving epigenetic reprogramming to a drug-resistant state in melanoma [110] and chemotherapy
enriching a CD24highCD4high drug-resistant population in breast cancer cells [79].
Mechanism-based mathematical models have helped tease out that this adaptive enrichment of a
drug-resistant cancer subpopulation can result from phenotypic plasticity, for instance, the emergence
of a drug-resistant CD24high/CD44high state [79]. The CD24high/CD44high state was also suggested to
associate with an elevated Notch-Jagged signaling, a prediction that has been validated experimentally
at least preliminarily [60]. Similarly, in an attempt to understand the experimentally observed
correlation between EMT and immune evasion, a mathematical model involving the transcription
factors STAT1, STAT3, and the microRNA miR-200 predicted and guided the experimental design for
how inhibiting STAT3 activation altered the levels of a set of immune-evasion mediators PSMB8 and
PSMB9 in the mesenchymal NSCLC cells [111]. Therefore, mathematical models can be valuable tools
in elucidating the principles of phenotypic plasticity governing both de novo and acquired resistance to
various therapies.
7. Role of Intrinsically Disordered Proteins in Phenotypic Plasticity
From the foregoing, it is obvious that cancer cells retain high plasticity which facilitates
phenotypic transitions among various phenotypes to adjust to microenvironments. A hallmark
of many master regulators that regulate cancer phenotypic plasticity such as, oncoproteins that cause
cellular transformation, factors that induce reprograming of somatic cells to pluripotent stem (iPS) cells,
and several EMT-TFs that play a critical role in EMT/MET is that, they are intrinsically disordered
proteins (IDPs) [20,112–114].
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IDPs are proteins, or large regions within ordered proteins, that lack three-dimensional structure.
They exist as ensembles instead but can transition from disorder to order upon interacting with a
biological target (reviewed in [115,116]). However, there are several cases where IDPs stochastically
sample the conformational state space a priori [117,118] or are functional even when remaining highly
disordered [119–122]. Regardless however, because IDPs populate multiple conformational states
albeit transiently, and display rapid conformational dynamics, they are prone to stochastically engage
in myriad “promiscuous” interactions, especially when they are overexpressed [123,124].
In an attempt to understand the roles of IDPs in cancer phenotypic plasticity, Mahmoudabadi et al. [125]
have suggested that these promiscuous interactions result in “noise” in the system. Further,
to distinguish this noise from the widely recognized “transcriptional noise” that stems from gene
expression, the authors coined the term “conformational noise”. This new source of biological
noise stems from IDP conformational dynamics and is an inherent characteristic of IDP interactions.
However, notwithstanding the distinction, the authors postulated that just like transcriptional noise
which plays an important role in generating phenotypic heterogeneity [126,127], the collective effect of
conformational noise is an ensemble of protein regulatory network configurations, from which the
most suitable configuration can be explored by the cancer cell to “make” appropriate decisions, thus
conferring it with remarkable phenotypic plasticity. Moreover, the ubiquitous presence of intrinsic
disorder in transcriptional factors and, more generally, in proteins that occupy hub positions in
regulatory networks is thought to be indicative of the role of IDPs in propagation and amplification
of transcriptional as well as other types of noise (e.g., noise in signaling pathways) in the system.
Therefore, as effectors of conformational and transcriptional noise, IDPs can rewire regulatory
networks unmasking latent regulatory circuits in response to perturbations and switch phenotypes to
generate phenotypic heterogeneity [125]. Thus, from Waddington’s epigenetic landscape perspective,
conformational noise-driven rewiring results in the system exploring the high-dimensional state space
and homing to attractor basins that harbor “cancer attractors”. Implicit in the model proposed by
Mahmoudabadi et al. [125], phenotypic switching can result from stochastic (non-genetic) rather than
by deterministic events alone (genetic), and the regulatory network configuration contains information
that can aid cell fate decisions.
In a recent paper, Mooney et al. [20] reviewed the role of IDPs in EMT and discussed how IDP
conformational dynamics can contribute to phenotypic plasticity using prostate cancer (PCa) as an
example. In addition, Kulkarni et al. [106] discussed the role of IDPs in the emergence of androgen
resistance (independence), yet another paradigm of phenotypic plasticity in PCa. Here, we highlight
their role in the emergence of androgen resistance.
The onset of androgen resistance in patients treated with androgen-deprivation therapy (ADT) is
a major impediment in PCa. However, the underlying molecular mechanisms are not fully understood.
To gain new insight, Kulkarni et al. [106] recently employed multiple biophysical approaches
that report conformational preferences of Prostate-Associated Gene 4 (PAGE4). PAGE4 is an IDP
that acts as a potentiator of the Activator Protein-1 (AP-1) transcription factor [128,129]. PAGE4
is phosphorylated by Homeodomain-Interacting Protein Kinase 1 (HIPK1) predominantly at T51
which is critical for its transcriptional activity [130]. However, PAGE4 is also hyperphosphorylated
by CDC-Like Kinase2 (CLK2) at multiple S/T residues including T51. Further, while HIPK1 is
expressed in both androgen-dependent and androgen-independent PCa cells, CLK2 and PAGE4
are expressed only in androgen-dependent cells. Cell-based reporter assays indicated that PAGE4
interaction with the two kinases leads to opposing functions. Thus, whereas HIPK1-phosphorylated
PAGE4 (HIPK1-PAGE4) potentiates c-Jun, CLK2-phosphorylated PAGE4 (CLK2-PAGE4) attenuates
c-Jun activity. Consistent with the cellular data, biophysical measurements employing small-angle
X-ray scattering, single-molecule fluorescence resonance energy transfer, and multidimensional NMR
indicated that HIPK1-PAGE4 exhibits a relatively compact conformational ensemble that binds AP-1,
whereas CLK2-PAGE4 is more expanded and resembles a random coil with diminished affinity for
AP-1 [106,128].
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AP-1 can negatively regulate androgen receptor (AR) activity [131,132], and AR can transcriptionally
inhibit CLK2 expression [106]. Furthermore, cells resistant to ADT often have enhanced AR activity
(AR protein expression can increase >25 fold) suggesting a positive correlation between ADT resistance
and AR activity [133]. These observations combined with the data [106] allowed the construction of a
circuit representing the PAGE4/AP-1/AR interactions and the development of a mathematical model
that represents the dynamics of this circuit.
The model predicts that the circuit can display sustained or damped oscillations suggesting that
androgen dependence of a cell need not be a fixed state and can vary temporally. Thus, contrary to the
prevailing deterministic model that tacitly assumes PCa cells to acquire an androgen-dependent or an
independent state (mutually exclusive “binary” model driven by genetic events), cells can enter or exit
the androgen-independent state or phenotype (it is reversible) (Figure 3). Even in the case of damped
oscillations that eventually settle to one state, the system can revert to displaying sustained oscillations
under the effect of biological “noise”. Such noise can originate from multiple sources such as, limited
quantities of PAGE4, HIPK1, or CLK2, and/or the conformational dynamics of PAGE4. Furthermore,
the model also predicts that the intracellular CLK2, HIPK1-PAGE4, and CLK2-PAGE4 oscillations
need not be synchronized across cells. Thus, individual cells in an isogenic population would have
varying levels of androgen dependence or independence at a given point in time consequently giving
rise to non-genetic phenotypic heterogeneity observed in a seemingly homogenous population of
PCa cells [134]. In other words, androgen dependence represents a trait whose values can display
a broad distribution across the population. Indeed, this predicted heterogeneity in the levels of
HIPK1, CLK2 and PAGE4 is corroborated by quantitative immunohistochemistry and qRT-PCR
data [106]. Thus, the model that is developed using the tools of nonlinear dynamics demonstrates
how differential phosphorylation of PAGE4 can lead to transitions between androgen-dependent
and androgen-independent phenotypes by altering the AP-1/androgen receptor regulatory circuit in
PCa cells. Although additional work needs to be done, the study underscores IDPs can stochastically
orchestrate phenotypic heterogeneity in PCa due to their conformational dynamics when overexpressed
or aberrantly expressed.
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Figure 3. IDP conformational dynamics and phenotypic heterogeneity in prostate cancer cells.
The stress-response kinase HIPK1 phosphorylates the IDP PAGE4 resulting in a relatively compact
PAGE4 ens mble (HIPK1-PAGE4) that can potenti te AP-1 in androgen-dependent cells. In contrast,
the dual-specificity kinase CLK2 hyperphosphorylates PAGE4 leading to a more random-like PAGE4
ensemble (CLK2-PAGE4) that attenuates AP-1 function. Mathematical modeling suggests that the
oscillatory dynamics of HIPK1-PAGE4, CLK2-PAGE4, and CLK2 in the circuit enable the cells to
transition from an androgen-dependent to an androgen-independent phenotype. This prediction is
supported by the experimentally observed heterogeneity in a population of isogenic PCa cells (see [106]
for details).
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8. Conclusions and Future Vision
Waddington’s epigenetic landscape initially depicting the differentiation process of stem cells
now have been used to understand the phenotypic plasticity in cancer cells. The regulatory network
underlying the landscape can give rise to various “attractors”, i.e., “stable states” corresponding
to different cell phenotypes, each of which is characterized by a unique gene expression pattern.
Emerging insights demonstrate that cancer cells are often behaving as “moving targets” and often
find new adaptive ways to resist therapeutic attacks. This search for “cancer attractors” that increase
their fitness and/or survival likelihood can be considered akin to “de-canalization”. “Canalization”
refers to buffering of biological noise during development, such that cellular phenotypes are
stabilized against genetic and/or environmental perturbations, and their variability is decreased [135].
Thus, “de-canalization” would imply supraphysiological plasticity that can make the “valleys” in
Waddington’s landscape more shallow (by decreasing the height of the ridge between “valleys”) [136],
thereby enabling stochastic sampling of the landscape by cells, hence disrupting the stable cellular
phenotypes obtained and maintained in specific niches.
“De-canalization” into “cancer attractors” can be facilitated by gene mutations that rewires the
underlying regulatory network. For example, both gain-of-function mutations in proto-oncogenes
RAS and MYC and loss-of-function mutations in tumor suppressor genes TP53 and BRCA1 can trigger
abnormal cell growth and provoke cancer formation [12]. Once cells enter “cancer attractors”, they
acquire high cellular plasticity that allows phenotypic transitions to adjust to the microenvironment.
The high plasticity in cancer can be promoted by (a) increased biological noise due to the intrinsic
variability in gene expression [137] and the conformational dynamics of intrinsically disordered
proteins, such as oncoproteins, reprogramming TFs and EMT-TFs in cancer cells [20,112–114];
(b) the changed physiological parameters for cancer cells due to the modified microenvironment [138].
For example, cancer cells usually face hypoxia condition due to their rapid proliferation and the hypoxia
condition stabilizes HIF-1. This can then promote cancer cells to acquire a hybrid OXPHOS/glycolysis
phenotype that has been shown to be associated with higher metastatic potential as compared with only
OXPHOS or glycolysis phenotypes [91]. The high phenotypic plasticity of cancer cells can contribute
to metastasis and therapeutic failure.
Recent studies have also highlighted that phenotypic transitions do not have to be cell-autonomous
events. Instead, the microenvironment of a cell can often modulate such phenotypic switching,
for instance, (a) the lineage commitment of naïve mesenchymal stem cells can be directed by the
matrix elasticity and soft matrices generate nerve-like cells, stiff matrices generate muscle-like cells
and rigid matrices generate bone-like cells [139], (b) simulated microgravity can dramatically alter
the cytoskeletal architecture of MDA-MB-231 cells with consequent effects on proliferation and
apoptosis [140], (c) parallel microgrooves on the surface of cell-adhesive substrates can mechanically
modulate a cell’s epigenetic state and induce an MET, thereby increasing the efficiency of cellular
reprogramming [141], and (d) signals from mammary microenvironment can overrule the ‘terminal
commitment’ of a stem cell belonging to a “foreign” tissue [142]. Together, these studies highlight the
need to revisit whether a cell is ever “terminally differentiated”, and how much cell-autonomy there is
in a cell-fate [143].
9. Therapeutic Approach That Promotes “Re-canalization”
Can cells transition from “cancer attractors” back to “normal attractors”, i.e., “re-canalization”?
The answer seems to be yes based on some existing data. First, inactivation of the oncogene MYC
in hepatocellular carcinoma cells leads to the formation of normal hepatic structures [144]. Second,
decreasing the intracellular levels of TCTP (transcriptionally controlled tumor protein) is sufficient to
revert the malignancy of MCF7 or T47D cells (breast cancer), U937 cells (histiocytic lymphoma) [145]
and v-Src-transformed NIH3T3 cells (fibroblasts) [146], partially through recovering the function
of the P53/MDM2 axis [147]. Third, replacement of mitochondria in metastatic triple negative
breast cancer cells SUM159 with mitochondria from benign breast cancer cells MCF10A or A1N4
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abolish cell migration potential and in vivo tumor formation potential [90]. Forth, modification of
the surface integrins of human breast cancer cells in 3-dimensional culture results in a reversion to a
normal cell phenotype both morphologically and functionally despite the malignant genome [148].
Therefore, we believe that targeting the sources for phenotypic plasticity in cancer cells, for instance,
deactivation of oncoproteins and/or modification of tumor microenvironment can contribute to
the “re-canalization”.
Even though it may be difficult to revert cancer cells directly to normal cells, we can still
help cancers cells transition out from highly aggressive “attractors”. One possible approach is to
perturb factors that help maintain the aggressive “cancer attractors”. For example, knockdown of
the phenotypic stability factors OVOL and GRHL2 in H1975 cells can destabilize the hybrid E/M
phenotype [54], the “primary bad actors” of metastasis [43,44,46]. Therefore, instead of targeting
individual signaling pathways with insufficient knowledge of how they impinge on the epigenetic
landscape for each cell, future therapeutic approaches might consider a stepwise approach from the
dynamical systems perspective, start with the destabilization of the “cancer attractors”, followed by
transitions into “normal attractors”, then deepening the basin of attraction of “normal attractor” to
prevent future tumor relapse. As attractive as it may seem, the proposed approach remains to be
clarified on the basis of combined modeling and experimental work.
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